CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for GO-DX Corporation (Aust) Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

GO-DX Corporation (Aust) Ltd
505 Little Collins Street, Level 6
MELBOURNE, VIC  3000  Australia Ticker: GD8GD8
Business Summary
GO-Dx Corporation (Aust) Ltd is an Australia-based healthcare technology company specializing in advanced diagnostic and precision medicine solutions. The Company has developed intellectual property comprising an RNA mining/mapping platform designed as a tool to support personalized diagnostics and therapeutics. The RNA Mining/Mapping Platform is a diagnostic tool created for the specific purposes of generating personalized ribonucleic acid (RNA) information for individuals in the form of a graph. Its products include a range of nutraceutical products which are designed to improve health and wellness. Its products are G’Nest Deluxe and G’Nest Premium, and C’Neuros. Its services include RNA Mining/Mapping & Analytics Platform, Al-Enabled Platform, Cancer screening and diagnostics, Neurological and immunological precision medicine via proprietary genetic and epigenetic screening and diagnostic platforms, and Liquid biopsy based diagnostics for cancers using NGS technology.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024-----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Group Managing Director, Executive Chairman of the Board, Chief Executive Officer Kah MengLim
Chief Financial Officer Hock KiongHeng
Chief Scientific Officer Eng LeeTan
4 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 163,003,500 (As of 6/30/2024)
Stock Exchange: NSX


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, January 20, 2025